Main uses and guidelines for use of giritinib

Gilitinib is an advanced anti-tumor drug designed to treat patients with acute myeloid leukemia (AML) who carry FLT3 mutations. AML is a severe hematological malignancy, in which a high proportion of FLT3 gene mutations lead to abnormal proliferation of leukemia cells, making traditional treatments often ineffective. Giritinib was born based on in-depth research on the mutation mechanism of FLT3. It effectively blocks the signal transduction of leukemia cells by specifically inhibiting the kinase activity of FLT3, bringing new treatment hope to patients.

When using gilitinib, patients should strictly follow their doctor's instructions. Typically, this medication is taken by mouth once daily at a recommended dose of 120 mg. Patients can choose to take it with a meal or on an empty stomach, but be sure to swallow the tablet whole and never break or crush the tablet. In order to maintain a stable drug concentration in the blood, it is recommended that patients take the drug at a similar time every day, such as after breakfast or lunch. It should be noted that treatment response may be delayed, therefore, in the absence of disease progression or unacceptable toxicity, patients should adhere to treatment for at least 6 months to ensure sufficient time to observe clinical response.

During the use of giritinib, patients may encounter some adverse reactions, which may include elevated transaminase, myalgia/arthralgia, fatigue/ malaise, fever, mucositis, edema, rash, non-infectious diarrhea, dyspnea, nausea, cough, etc. When these adverse reactions occur, patients should communicate with the attending doctor in a timely manner so that the doctor can adjust the treatment plan or take corresponding symptomatic treatment measures according to the patient's specific situation.

In addition, although giritinib has been marketed in China, it has not yet been included in the medical insurance catalog. Its market price is high, which may bring greater financial pressure to patients. However, affordable generic drugs are already available in the Lao market, which can reduce the financial burden on patients to a certain extent. Patients are asked to choose purchasing channels reasonably based on their own needs and financial status.

In summary, giritinib, as a targeted drug targeting FLT3 mutation-positive AML, provides a new treatment option for patients carrying this mutation. However, during use, patients need to strictly follow medical instructions and pay attention to the adverse reactions and price factors of the drug in order to better control the disease and reduce the financial burden.